Thalidomide

Search with Google Search with Bing

Information
Drug Name
Thalidomide
Description
Entry(CIViC)
CIViC
[No Data.]
Annotation
Description Associated Genes Associated Variants Sensitivity Supported Source Links
IFN-alpha2b and thalidomide synergistically inhibi... IFNAR1 IFNAR1 OVEREXPRESSION Sensitivity true MMMP detail
In this phase II trial, no objective responses wer... IFNAR1 IFNAR1 OVEREXPRESSION Resitance or Non-Reponse true MMMP detail
NCT ID Status Phase Summary Start date Completion date
NCT03069326 Active, not recruiting Phase 2 A Clinical Study to Test the Effects of Ruxolitinib And Thalidomide Combination for Patients With Myelofibrosis February 27, 2017 February 2025
NCT00098475 Active, not recruiting Phase 3 Lenalidomide and Dexamethasone With or Without Thalidomide in Treating Patients With Multiple Myeloma November 3, 2004 October 22, 2024
NCT03004287 Active, not recruiting Phase 2 2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy July 1, 2017 October 2025
NCT00871013 Active, not recruiting Phase 2 Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy March 2009 December 2024
NCT00869232 Active, not recruiting Phase 2 UARK 2008-02 A Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Complete Remission October 2008 October 2024
NCT00602641 Active, not recruiting Phase 3 Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma February 29, 2008 February 22, 2025
NCT00572169 Active, not recruiting Phase 3 UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy November 2006 August 2025
NCT00002127 Completed Phase 2 A Phase II, Parallel Group, Randomized, Placebo-Controlled Study of the Safety and Efficacy of Thalidomide in Reducing Weight Loss in Adults With HIV Wasting Syndrome
NCT00002157 Completed N/A Compassionate Use Study of Two Dose Levels of Thalidomide in Adults With HIV Wasting Syndrome
NCT00002174 Completed N/A Further Evaluation of Thalidomide's Ability to Potentiate the Immune Response to HIV-Infected Patients
NCT00002392 Completed N/A A Study of Thalidomide in HIV-Infected Patients Who Are Receiving HAART
NCT00003754 Completed Phase 2 Thalidomide and Cyclophosphamide in Treating Children With Recurrent or Refractory Childhood Cancers September 1998 July 2001
NCT00003850 Completed Phase 2 Thalidomide in Treating Patients With Recurrent or Metastatic Head and Neck Cancer April 1999
NCT00003894 Completed Phase 2 Thalidomide in Treating Patients With Chronic Graft-Versus-Host Disease Following Bone Marrow Transplant March 1999 June 2002
NCT00004088 Completed Phase 2 Combination Chemo, Peripheral Stem Cell Transplant, Biological Therapy, Pamidronate and Thalidomide for Multiple Myeloma April 13, 1999 January 9, 2018
NCT00004276 Completed Phase 2 Phase II Placebo Controlled Study of Thalidomide in Patients With Mycobacterial and HIV Infections September 1990 June 1999
NCT00004450 Completed N/A Randomized Study of Beta Interferon and Thalidomide in Patients With Adrenoleukodystrophy August 1998 November 2000
NCT00004635 Completed Phase 3 Thalidomide for the Treatment of Hormone-Dependent Prostate Cancer March 1, 2000 March 30, 2010
NCT00004876 Completed Phase 2 Carboplatin With or Without Thalidomide in Treating Patients With Ovarian Epithelial Cancer August 1999
NCT00005815 Completed Phase 1/Phase 2 Temozolomide and Thalidomide in Treating Patients With Stage III or Stage IV Melanoma December 1999 August 2004
NCT00005966 Completed Phase 3 Interferon Alfa-2b With or Without Thalidomide in Treating Patients With Metastatic or Unresectable Kidney Cancer October 2000
NCT00006005 Completed Phase 2 Thalidomide in Treating Patients With Gynecologic Sarcomas September 2000 August 2006
NCT00006006 Completed Phase 2 Thalidomide Plus Interferon Alfa in Treating Patients With Progressive Liver Cancer That Cannot be Surgically Removed August 2000
NCT00006016 Completed Phase 2 Thalidomide and Chemoembolization With Doxorubicin in Treating Patients With Liver Cancer That Cannot be Removed by Surgery May 2000 April 2005
NCT00006226 Completed Phase 2 Thalidomide in Treating Patients With Relapsed Chronic Lymphocytic Leukemia September 2000
NCT00006358 Completed Phase 2 Temozolomide Plus Thalidomide in Treating Patients With Recurrent or Progressive Brain Tumor June 13, 2000 July 20, 2006
NCT00006890 Completed Phase 2 Thalidomide and Prednisone Following Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma July 12, 2000 December 15, 2008
NCT00008242 Completed Phase 2 Thalidomide, Doxorubicin, and Dexamethasone in Treating Patients With Untreated Stage II or Stage III Multiple Myeloma August 2000 January 2006
NCT00015821 Completed Phase 2 Thalidomide in Treating Patients With Myelofibrosis May 2000
NCT00015990 Completed Phase 2 Thalidomide in Treating Patients With Myelodysplastic Syndrome April 2001
NCT00016224 Completed Phase 2 Thalidomide in Treating Patients With Refractory or Resistant Epithelial Ovarian Cancer January 2001 March 2004
NCT00017316 Completed Phase 2 Thalidomide and SU5416 in Treating Patients With Metastatic Melanoma March 2001
NCT00019123 Completed Phase 2 Thalidomide in Treating Patients With HIV-Associated Kaposi's Sarcoma April 1996 April 2004
NCT00019539 Completed Phase 2 Monoclonal Antibody Therapy in Treating Patients With Advanced Kidney Cancer November 1998 November 2004
NCT00000790 Completed Phase 2 Thalidomide for Treatment of Oral and Esophageal Aphthous Ulcers and HIV Viremia in Patients With HIV Infection October 1998
NCT00000812 Completed Phase 1 A Phase I, Placebo-Controlled, Dose-Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Thalidomide in Subjects With HIV-1 Infection July 2000
NCT00001446 Completed Phase 2 A Randomized Phase II Study of Oral Thalidomide in Patients With Hormone-Refractory Prostate Cancer September 1995 July 2001
NCT00001524 Completed Phase 2 Thalidomide to Treat Oral Lesions in HIV-Infected Patients June 1996 December 2004
NCT00001599 Completed Phase 2 Pilot Study of Thalidomide to Treat Sjogren's Syndrome May 1997 June 2002
NCT00001680 Completed Phase 2 A Pilot Trial of Topical Thalidomide for the Management of Chronic Discoid Lupus Erythematosus October 1997 July 2001
NCT00002104 Completed Phase 1 Placebo-Controlled Trial of Safety and Efficacy of Thalidomide in Patients With Infections Due to Mycobacterium and/or HIV
NCT00062127 Completed Phase 1 Irinotecan and Thalidomide in Treating Patients With Advanced Solid Tumors April 2003
NCT00064337 Completed Phase 2 S0115, High-Dose Melphalan and Autologous Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Primary Systemic Amyloidosis January 2004 November 2015
NCT00072163 Completed Phase 2 Temozolomide and Thalidomide in Treating Patients With Brain Metastases Secondary to Melanoma October 2003
NCT00072345 Completed Phase 2 Temozolomide, Thalidomide, and Lomustine in Treating Patients With Unresectable Stage III or Stage IV Melanoma July 2003
NCT00075829 Completed Phase 3 Stem Cell Transplantation in Individuals With Multiple Myeloma (BMT CTN 0102) December 2003 March 2013
NCT00079092 Completed Phase 2 Thalidomide and Procarbazine in Treating Patients With Recurrent or Progressive Malignant Glioma January 1, 2004 March 21, 2006
NCT00081757 Completed Phase 1/Phase 2 An Open Protocol for the Compassionate Use of Thalidomide September 1998 May 2005
NCT00081939 Completed Phase 2 UARK 2003-33, Total Therapy III January 2004 September 2014
NCT00083005 Completed Phase 2 Docetaxel, Estramustine, and Thalidomide in Treating Patients With Androgen-Independent Metastatic Adenocarcinoma of the Prostate March 2004 December 2007
NCT00083382 Completed Phase 2 Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide December 1998 May 2014
NCT00083408 Completed Phase 2 Combination Bisphosphonate and Anti-Angiogenesis Therapy With Pamidronate and Thalidomide March 1998 May 2005
NCT00083460 Completed Phase 1 Study of Combination PS-341 and Thalidomide in Multiple Myeloma December 2001 November 2007
NCT00083538 Completed Phase 2 Study of Tumor Antigen-Pulsed Autologous Dendritic Cell Vaccination Administrated Subcutaneously or Intranodally February 2001 December 2007
NCT00083551 Completed Phase 3 UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy August 1998 August 2014
NCT00083577 Completed Phase 2 Anti-Angiogenesis Therapy Using Thalidomide in Multiple Myeloma February 1998 May 2005
NCT00083681 Completed Phase 2 DCEP in Combination With Thalidomide as Salvage Therapy for Post Transplantation Relapse June 1998 May 2005
NCT00083694 Completed Phase 2 Thalidomide Anti-Angiogenesis Therapy of Relapsed or Refractory Leukemia August 1998 May 2005
NCT00083707 Completed Phase 2 Anti-Angiogenesis Therapy Using Thalidomide in Patients With Waldenstrom's Macroglobulinemia January 1999 February 2003
NCT00083876 Completed Phase 3 D.T. PACE Versus High Dose Melphalan and Autologous Transplant in Patients With Previously Treated Multiple Myeloma September 1998 November 2007
NCT00083902 Completed Phase 2 Dexamethasone or Dexamethasone in Combination With Thalidomide as Salvage Therapy June 1998 May 2005
NCT00083915 Completed Phase 3 DTPACE Followed by Tandem Transplant With Melphalan (MEL) 200 Versus MEL/Dexamethasone/Thalidomide (DT) Platinol/Adriamycin/Etoposide (PACE) Hybrid and DTPACE Consolidation June 2001 June 2010
NCT00089167 Completed Phase 2 Melphalan, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed, Previously Untreated Primary Systemic Amyloidosis May 2002
NCT00089609 Completed Phase 2 Docetaxel, Thalidomide, Prednisone, and Bevacizumab to Treat Metastatic Prostate Cancer April 19, 2005 January 9, 2018
NCT00096018 Completed Phase 1/Phase 2 Fludarabine and Thalidomide in Treating Patients With Newly Diagnosed Chronic Lymphocytic Leukemia May 2002 May 2012
NCT00097981 Completed Phase 3 A Study of Thalidomide Plus Dexamethasone (Thal-Dex) Versus DOXIL plusThalidomide Plus Dexamethasone (DOXIL -Thal-Dex) in Patients With Newly Diagnosed Multiple Myeloma January 2005 October 2009
NCT00098865 Completed Phase 2 Thalidomide and Temozolomide in Relapsed or Progressive CNS Disease or Neuroblastoma September 2002 June 2010
NCT00104988 Completed Phase 2 S0508: Thalidomide and Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery June 2005 August 2009
NCT00112502 Completed Phase 2 Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme September 2005 September 2014
NCT00114192 Completed Phase 2 Docetaxel and Thalidomide as Second-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer June 2004
NCT00140452 Completed Phase 2 Phase II Study Using Thalidomide for the Treatment of ALS February 2005 November 2007
NCT00142116 Completed Phase 2 Thalidomide and Rituximab in Waldenstrom's Macroglobulinemia May 2003 February 2008
NCT00151281 Completed Phase 2 Phase II Study of RT-PEPC in Relapsed Mantle Cell Lymphoma November 2004 April 7, 2011
NCT00162760 Completed Phase 2 Treatment of Idiopathic Pulmonary Fibrosis With Thalidomide October 2003 July 2007
NCT00165217 Completed Phase 2 Capecitabine and Thalidomide in Previously Treated Metastatic Colorectal Carcinoma November 2001 December 2005
NCT00165230 Completed Phase 2 Thalidomide in Combination With Temodar in Patients With Neuroendocrine Tumors May 2002 July 2006
NCT00165451 Completed Phase 2 A Trial of Thalidomide, Celecoxib, Etoposide and Cyclophosphamide in Patients With Relapsed or Progressive Cancer June 2001 October 2006
NCT00182663 Completed Phase 2 Thalidomide, Dexamethasone, and Clarithromycin in Treating Patients With Multiple Myeloma Previously Treated With Transplant June 2003
NCT00193544 Completed Phase 2 Arsenic Trioxide and Thalidomide in the Treatment of Refractory Multiple Myeloma March 2002 January 2009
NCT00218855 Completed Phase 3 Thalidomide to Patients With Previously Untreated Multiple Myeloma January 2002 April 2007
NCT00222053 Completed Phase 3 IFM 99-02 Thalidomide in Myeloma April 2000 December 2009
NCT00222105 Completed Phase 2 A Study Evaluating Efficacy, Toxicity, Harvest Yield and Quality of Life November 2002 July 2009
NCT00226980 Completed Phase 2 A Trial of Thalidomide and Capecitabine in Metastatic Renal Cell Carcinoma October 2002 July 2006
NCT00232934 Completed Phase 3 Melphalan, Prednisone and Thalidomide Versus Melphalan and Prednisone in Elderly Myeloma Patients January 2002 November 2014
NCT00238329 Completed Phase 2 PEG-Interferon Alfa-2b and Thalidomide in Treating Patients With Recurrent or Metastatic Melanoma January 2001 June 2007
NCT00251797 Completed Phase 1 A Phase I Trial Using Combination Irinotecan and Thalidomide for Recurrent CNS Tumors March 2000 June 2006
NCT00258245 Completed Phase 1 Arsenic Trioxide and Ascorbic Acid Combined With Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia May 2005 April 2008
NCT00263484 Completed Phase 2 Higher Frequency Zoledronic Acid in the Treatment of Multiple Myeloma December 2005 October 2010
NCT00274820 Completed Phase 2 Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Myelofibrosis/Myeloproliferative Disorder October 2005 October 2007
NCT00284505 Completed Phase 2 Use of Thalidomide in Patients With Arachnoiditis July 2005 July 2006
NCT00287872 Completed Phase 2 Bortezomib and Thalidomide in Treating Patients With Newly Diagnosed Stage II or Stage III Multiple Myeloma September 2004 November 2010
NCT00305552 Completed Phase 3 SARCOTHAL. Thalidomide in Skin Sarcoidosis February 2005 November 2007
NCT00307294 Completed Phase 2 Thalidomide and Doxil® in Patients With Androgen Independent Prostate Cancer (AIPC) March 2006 January 2012
NCT00310076 Completed Phase 2 Thalidomide in Treating Patients Who Have Undergone Surgery and Chemotherapy for Cancer That Has Spread Throughout the Abdomen Due to Colorectal Cancer or Appendix Cancer October 2002 September 2012
NCT00357500 Completed Phase 2 Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer January 2005 December 2013
NCT00358020 Completed Phase 2 Melphalan, Prednisone, Thalidomide And Bortezomib In Advanced And Refractory Multiple Myeloma Patients November 2004 December 2008
NCT00367185 Completed Phase 3 Treatment of Newly Diagnosed Elderly Patients With Multiple Myeloma May 2000 October 2005
NCT00379353 Completed Phase 2 The Effects of Thalidomide on Symptom Clusters September 2006 January 2013
NCT00389935 Completed Phase 2 Thalidomide Reduces Arteriovenous Malformation Related Gastrointestinal Bleeding October 2006 July 2011
NCT00400517 Completed Phase 2 GM-CSF and Thalidomide in Treating Patients Undergoing Surgery for High-Risk Prostate Cancer March 2003 June 2008
NCT00406978 Completed Phase 1/Phase 2 Melphalan, Prednisone, Thalidomide and Defibrotide in Relapsed Multiple Myeloma Patients February 2006 April 2014
NCT00412542 Completed Phase 2 Thalidomide and Temozolomide or Camptothecin-11 (CPT-11) in Patients With Gliomas October 2003 October 2009
NCT00432458 Completed Phase 3 Zoledronate With or Without Thalidomide in Treating Patients With Early Stage Multiple Myeloma July 2003 April 2012
NCT00445900 Completed Phase 2 Thalidomide, Prednisone, and Cyclophosphamide in Treating Patients With Myelofibrosis and Myeloid Metaplasia October 2004 October 2006
NCT00450801 Completed Phase 2 R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma April 2004 July 2015
NCT00452569 Completed Phase 3 Efficacy and Safety Study of 3 Thalidomide Doses for the Treatment of Relapsed Refractory Multiple Myeloma February 1, 2006 January 1, 2009
NCT00455910 Completed Phase 2 Thalidomide at Low Dose for the Treatment of Patient With Myelodysplastic Syndromes - THAL-SMD-200 January 2003 March 2007
NCT00458705 Completed Phase 2 Bortezomib, Doxorubicin Hydrochloride Liposome, and Dexamethasone Followed by Thalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Multiple Myeloma November 2006 April 2011
NCT00507416 Completed Phase 3 Velcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus Velcade, Melphalan, and Prednisone June 2007 March 2013
NCT00519688 Completed Phase 2 UFUR Plus Thalidomide for Advanced Hepatocellular Carcinoma July 2006 August 2010
NCT00523848 Completed Phase 2 Bortezomib, Doxorubicin Hydrochloride Liposome, and Thalidomide as First-line Therapy in Treating Patients With Previously Untreated Stage I, II, or III Multiple Myeloma June 2006 October 2012
NCT00527657 Completed Phase 1 Temozolomide, Thalidomide, and Lomustine (TTL) in Melanoma Patients February 9, 2006 February 2, 2012
NCT00577096 Completed N/A Effects of Exercise in Combination With Epoetin Alfa October 2001 June 2004
NCT00600028 Completed Phase 3 Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis With Thalidomide December 2007 September 2011
NCT00602511 Completed Phase 3 Thalidomide Versus Bortezomib in Melphalan Refractory Myeloma October 2007 December 2010
NCT00633542 Completed Phase 3 Maintenance Therapy After Thalidomide-Dexamethasone(ThaDD) for Multiple Myeloma(MM) June 2003 October 2007
NCT00652041 Completed Phase 4 Bortezomib/Adriamycine/Melfalan/Prednisone (VAMP)/Thalidomide/Cyclophosphamide/Dexamethasone (TaCyDex) or Bortezomib/Melfalan/Prednisone (V-MP)/TaCyDex) in Refractary or Relapsed Multiple Myeloma January 2007 June 2010
NCT00657488 Completed Phase 2/Phase 3 Thalidomide 100 mg/Day Versus Thalidomide 400 mg/Day in Relapse Refractory Multiple Myeloma December 1, 2001 April 1, 2006
NCT00720538 Completed Phase 3 Thalidomide in Pediatric Inflammatory Bowel Diseases. August 2008 June 2012
NCT00769587 Completed Phase 2 Thalidomide in Treating Patients With Relapsed or Progressive Systemic Mastocytosis June 2007 October 2012
NCT00792142 Completed Phase 2 Bortezomib, Thalidomide, and Dexamethasone After Melphalan and Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma January 16, 2008 April 21, 2014
NCT00934154 Completed Phase 3 Melphalan+Prednisolon With or Without Thalidomide in Previously Untreated Elderly Patients With Multiple Myeloma March 2006 September 2012
NCT00964496 Completed Phase 2 Long-term Effects of Thalidomide for Recurrent Gastrointestinal Bleeding Due to Vascular Malformation November 2004 August 2009
NCT00966693 Completed Phase 1/Phase 2 Lenalidomide, Thalidomide and Dexamethasone in Treating Participants With Relapsed or Refractory Multiple Myeloma August 25, 2009 July 20, 2018
NCT01057225 Completed Phase 1/Phase 2 Cyclophosphamide, Carfilzomib, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Active Multiple Myeloma March 2010 September 5, 2017
NCT01125176 Completed Phase 2 Alternating Thalidomide and Lenalidomide Therapy Plus Rituximab (ThRiL) as Initial Treatment for Patients With CLL March 30, 2012 December 29, 2020
NCT01341262 Completed Phase 2 THAL-DEX Incorporated Into Double PBSC Autotransplantation for Untreated Multiple Myeloma (MM) March 2002 January 2009
NCT01485224 Completed Phase 2 Efficacy of Thalidomide in the Treatment of Hereditary Hemorrhagic Telangiectasia November 2011 October 11, 2016
NCT01526694 Completed Phase 2 Phase II Trial Designed to Determine Efficacy and Safety of Bendamustine+Dexamethasone+Thalidomide in R/R MM July 2012 April 8, 2017
NCT01539083 Completed Phase 3 Velcade (Bortezomib) Consolidation After Transplant January 13, 2012 January 9, 2018
NCT01632150 Completed Phase 2 Safety Study of Elotuzumab in Combination With Thalidomide and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma May 2012 March 2016
NCT01661400 Completed Phase 1 Anti-Angiogenic Therapy Post Transplant (ASCR) for Pediatric Solid Tumors October 26, 2012 December 27, 2023
NCT01849783 Completed Phase 2 Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma April 4, 2013 September 30, 2020
NCT01998971 Completed Phase 1 A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma February 18, 2014 January 11, 2024
NCT02203253 Completed Phase 3 Efficacy of Thalidomide in Preventing Chemotherapy-induced Delayed Nausea and Vomiting July 2014 August 2016
NCT02410694 Completed Phase 2 Ixazomib in Combination With Thalidomide - Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma April 2015 May 2, 2019
NCT02424851 Completed Phase 2 Optimising Renal Outcome in Myeloma Renal Failure November 2014 April 20, 2020
NCT02501291 Completed Phase 2 Thalidomide in Treating Crohn's Disease January 2013 April 2015
NCT02507336 Completed Phase 2 Long-Term Followup and/or Thalidomide Maintenance Therapy for Patients Enrolled on Clinical Trial 20030165 November 24, 2015 August 2, 2023
NCT02545907 Completed Phase 1/Phase 2 A Dose Escalation Study of Carfilzomib Taken With Thalidomide and Dexamethasone in Relapsed AL Amyloidosis September 14, 2017 October 21, 2019
NCT02586038 Completed Phase 2 STUDY THAT COMPARE 3 ARM: MLN9708 DEXAMETHASONE, MLN9708 CYCLOPHOSPHAMIDE AND DEXAMETHASONE, MLN9708 THALIDOMIDE AND DEXAMETHASONE FOLLOWED BY MAINTENANCE WITH MLN9708 IN NEWLY DIAGNOSED ELDERLY MULTIPLE MYELOMA PATIENTS October 2015 December 2023
NCT02891811 Completed Phase 2 Patients With Newly Diagnosed Multiple Myeloma Comparing KTd vs. KRd Induction Therapy and Investigating a K-mono Maintenance Strategy March 10, 2017 March 28, 2024
NCT03122431 Completed Phase 4 Relevance of Monitoring Blood and Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases June 5, 2017 March 30, 2021
NCT06146478 Completed Phase 3 Deciphering Effects of Thalidomide on Red Blood Cells in Transfusion Dependents Beta Thalassemia Patients January 25, 2022 October 31, 2023
NCT00020046 Completed Phase 2 Docetaxel With or Without Thalidomide in Treating Patients With Metastatic Prostate Cancer December 1999 September 2003
NCT00022581 Completed Phase 2 Thalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma July 2001
NCT00022607 Completed Phase 2 Bevacizumab With or Without Thalidomide in Treating Patients With Relapsed or Refractory Multiple Myeloma January 2002 May 2006
NCT00023530 Completed N/A Blood and Marrow Transplant Clinical Research Network September 2001 August 2006
NCT00025220 Completed Phase 2 Thalidomide in Treating Patients With Recurrent or Persistent Cancer of the Uterus September 2001 July 2008
NCT00025285 Completed Phase 2 Combination Chemotherapy Plus Thalidomide in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer November 1, 2001 September 29, 2004
NCT00025467 Completed Phase 2 Thalidomide in Treating Patients With Recurrent or Persistent Endometrial Cancer September 2001
NCT00025506 Completed Phase 2 Thalidomide in Treating Patients With Recurrent or Persistent Carcinosarcoma of the Uterus September 2001 January 2013
NCT00026520 Completed Phase 2 Interferon Alfa and Thalidomide in Treating Patients With Stage IV Melanoma November 2001 April 2006
NCT00026533 Completed Phase 2 Thalidomide in Treating Patients With Thyroid Cancer June 2001 December 2005
NCT00027638 Completed Phase 2 Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors March 2001 December 2003
NCT00030550 Completed Phase 2 Thalidomide in Treating Anemia in Patients With Myelodysplastic Syndrome September 2001
NCT00033254 Completed Phase 3 Radiation Therapy With or Without Thalidomide in Treating Patients With Brain Metastases March 2002
NCT00033332 Completed Phase 3 Dexamethasone With or Without Thalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma April 2002 June 2006
NCT00038090 Completed Phase 2/Phase 3 Thalidomide-Dexamethasone for Multiple Myeloma June 2000 May 2005
NCT00038181 Completed Phase 2 Preoperative Thalidomide Followed By Radical Retropubic Prostatectomy In Select Patients With Locally Advanced Prostate Cancer October 5, 2000 November 29, 2005
NCT00038233 Completed Phase 3 Thalidomide for Multiple Myeloma May 1999 April 2005
NCT00038246 Completed Phase 1/Phase 2 Study of Paclitaxel, Estramustine Phosphate and Thalidomide for Patients With Metastatic Androgen-Independent Prostate Carcinoma October 2000 December 2004
NCT00039468 Completed Phase 2 Thalidomide and Irinotecan in Treating Patients With Glioblastoma Multiforme Who Have Undergone Radiation Therapy March 2002 February 2008
NCT00040937 Completed Phase 2 S0204 Thalidomide, Chemotherapy, and Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma June 2002 October 2015
NCT00041080 Completed Phase 3 Tamoxifen Compared With Thalidomide in Treating Women With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer February 2003 January 2011
NCT00046826 Completed Phase 2 Docetaxel, Estramustine, and Thalidomide in Treating Patients With Prostate Cancer Previously Treated With Hormone Therapy September 2001 October 2009
NCT00047281 Completed Phase 2 Thalidomide, Celecoxib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Malignant Glioma March 2004 February 2006
NCT00047294 Completed Phase 2 Temozolomide, Thalidomide, and Celecoxib Following Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme April 2001 September 2007
NCT00047879 Completed Phase 2 Phase II Trial of Peginterferon Alpha-2b and Thalidomide in Adults With Recurrent Gliomas October 2002 June 2009
NCT00049296 Completed Phase 1 Thalidomide and Docetaxel in Treating Patients With Advanced Cancer July 2002 January 2006
NCT00049361 Completed Phase 2 Radiation Therapy Plus Thalidomide and Temozolomide in Treating Patients With Newly Diagnosed Brain Metastases January 1, 2004 December 7, 2004
NCT00049374 Completed Phase 2 Oblimersen, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma September 2002 January 2006
NCT00049673 Completed Phase 3 Thalidomide and Prednisone After Autologous Stem Cell Transplantation Multiple Myeloma October 15, 2002 September 19, 2013
NCT00050843 Completed Phase 3 A Study to Access the Safety/Efficacy of Thalidomide in the Treatment of Anemia in Patients With Myelodysplastic Syndromes August 2001 February 2004
NCT00052416 Completed Phase 1 Thalidomide in Treating Patients With Asymptomatic, Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia October 2002 January 2003
NCT00053001 Completed Phase 2 Thalidomide and Epoetin Alfa in Treating Anemia in Patients With Myelodysplastic Syndrome June 2001 October 2007
NCT00053287 Completed Phase 2 Fludarabine/Carboplatin/Topotecan w/Thalidomide for Relapsed/Refractory AML, CML and MDS September 2002 March 2007
NCT00053300 Completed Phase 2 Thalidomide in Treating Patients With Extensive-Stage Small Cell Lung Cancer August 2002 April 2010
NCT00053430 Completed Phase 2 Using the Drug Thalidomide to Stimulate T Cells in HIV-Infected People April 2001 February 2006
NCT00054158 Completed Phase 2 Combination Chemotherapy and Thalidomide in Treating Patients With Stage I, Stage II, or Stage III Multiple Myeloma August 2004
NCT00058487 Completed Phase 2 Epirubicin and Thalidomide in Treating Patients With Liver Cancer December 2001 January 2007
NCT06382519 Not yet recruiting Thalidomide Therapy for VEOIBD May 15, 2024 December 31, 2026
NCT04891744 Not yet recruiting Phase 1/Phase 2 Selinexor in Combination With Thalidomide and Dexamethasone in RRMM July 6, 2021 December 30, 2024
NCT05525234 Not yet recruiting Phase 4 A Study of Thalidomide in the Treatment of Refractory Uremic Pruritus September 15, 2022 January 31, 2023
NCT01356290 Recruiting Phase 2 Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma and ATRT April 2014 April 2026
NCT04352205 Recruiting Phase 2 Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure May 7, 2020 April 30, 2024
NCT06017284 Recruiting Phase 3 Thalidomide to Chemotherapy Related Nausea and Vomiting in Pancreatic Cancer November 1, 2023 November 30, 2026
NCT03759093 Recruiting Phase 2/Phase 3 CURATE.AI Optimized Modulation for Multiple Myeloma September 10, 2023 September 10, 2025
NCT06268093 Recruiting Phase 2 The Therapeutic Effect of Thalidomide in Syringomyelia February 2024 February 2028
NCT04941937 Recruiting Phase 2 Selinexor in Combination With Immunomodulator （Thalidomide/Pomalidomide/Lenalidomide）in RRMM January 27, 2022 December 30, 2025
NCT06299670 Recruiting Phase 4 Efficacy of Combination of Hdroxyurea and Thalidomide Over Either Hydroxyurea or Thalidomide Alone in the Treatment of Transfusion Dependent Thalassemia in Children: A Quasi-Randomised Clinical Trial November 1, 2023 December 31, 2024
NCT00004859 Terminated Phase 3 Carboplatin, Paclitaxel, and Radiation Therapy With or Without Thalidomide in Patients With Stage III Non-small Cell Lung Cancer January 2000 March 2010
NCT00301405 Terminated Phase 2 Open-Label Study of Thalidomide for Chronic Prostatitis/Chronic Pelvic Pain March 2006 November 2006
NCT01779167 Terminated Phase 2 Thalidomide, Lenalidomide, and Rituximab for Previously Treated Waldenstrom Macroglobulinemia June 2012 April 2014
NCT00469703 Terminated Phase 2 Safety and Efficacy Study of Thalomid in Patients With Chronic Pancreatitis August 2005 November 2007
NCT00953615 Terminated Phase 2 Thalidomide for the Treatment of Primary Sclerosing Cholangitis (PSC) April 2006 May 2009
NCT00505635 Terminated Phase 2 Biochemotherapy With Temozolomide for Metastatic Melanoma March 2007 April 2010
NCT00089544 Terminated Phase 2 Preoperative Thalidomide With Radiation Therapy For Patients With Low-Grade Primary Soft Tissue Sarcoma or Thalidomide With Radiation Therapy and Chemotherapy For Patients With High-Grade or Intermediate-Grade Primary Soft Tissue Sarcoma of the Arm, Leg, or Body Wall June 17, 2004 November 5, 2013
NCT00090870 Terminated Phase 2 PEG-Interferon Alfa-2b, Sargramostim, and Thalidomide in Treating Patients With Metastatic Kidney Cancer April 2002 March 2010
NCT01028781 Terminated Phase 1 Open Label of Thalidomide in Treatment of Women With Chronic Pelvic Pain Associated With Endometriosis October 2006 August 2009
NCT00015912 Terminated Phase 2 Interferon Alfa Plus Thalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma July 2001
NCT00215943 Terminated Phase 3 Phase III Randomized Trial of Thalidomide/Dexamethasone Versus Vincristine+Adriamycin+Dexamethasone (VAD) June 2003 August 2012
NCT00314665 Terminated Phase 4 Use of Thalidomide in Chronic Uveitis January 2004 August 2006
NCT00256776 Terminated Phase 3 MMVAR - Velcade: Study of Velcade for the Treatment of Myeloma Patients After Autologous Transplantation July 2005 December 2015
NCT00209014 Terminated Phase 2 Phase II Trial of Thalidomide in Refractory/Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin's Disease July 2003 June 2006
NCT03221166 Terminated Phase 3 Thalidomide Versus Infliximab in New Onset Crohn's Disease With Poor Prognostic Factors February 27, 2018 July 31, 2020
NCT00124579 Terminated Phase 2 S0417 Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma August 2005 June 2010
NCT00529633 Terminated Phase 3 The Effect of Thalidomide in Suppression of the Systemic Inflammatory Response Syndrome in Hemodialysis Patients September 2007 December 2009
NCT00019747 Terminated Phase 2 Surgery With or Without Thalidomide in Treating Patients With Recurrent or Metastatic Colorectal Cancer August 1999 December 2008
NCT00538824 Terminated Phase 2 Phase II Study of Dexamethasone, Thalidomide and Lenalidomide for Subjects With Relapsed or Refractory Multiple Myeloma December 2007 September 22, 2010
NCT00014443 Terminated Phase 2 Topotecan and Thalidomide in Treating Patients With Recurrent or Refractory Malignant Glioma August 2000 December 2003
NCT00193102 Terminated Phase 2 Thalidomide in Combination With Capecitabine in Patients With Metastatic Breast Cancer April 2001 June 2010
NCT01537861 Terminated Early Phase 1 Filgrastim in Treating Patients With Bortezomib-, Carfilzomib-, or IMID-Refractory Multiple Myeloma June 2012 December 2014
NCT01548573 Terminated Phase 2 Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment May 2012 August 2014
NCT00418132 Terminated Phase 1 Thalidomide for Decreasing Collagen Biosynthesis in People With Progressive Systemic Sclerosis August 2000 October 2007
NCT00009984 Terminated Phase 2 Thalidomide With or Without Fludarabine in Treating Patients With Hematologic Cancer March 2002
NCT00644306 Terminated Phase 3 Comparison of Melphalan-Prednisone (MP) to MP Plus Thalidomide in the Treatment of Newly Diagnosed Very Elderly Patients (> 75 Years) With Multiple Myeloma April 2002 May 2007
NCT00281827 Terminated Phase 2 Carboplatin, Gemcitabine, and Thalidomide in Patients Undergoing Surgery for Stage II or III Non-Small Cell Lung Cancer May 2002 July 2008
NCT00005834 Terminated Phase 3 S9922 Combination Chemo Plus Filgrastim With or Without Thalidomide in Refractory Multiple Myeloma April 2000 November 2007
NCT01927718 Terminated N/A Thalidomide to Overcome Lenalidomide Resistance After Autologous Hematopoietic Stem Cell Transplantation (HCT) January 2014 November 2016
NCT00227682 Terminated Phase 2 Arsenic Trioxide, Thalidomide, Dexamethasone, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma June 2004 February 2006
NCT00450008 Terminated Phase 2 Safety and Efficacy Study of GM-CSF, Thalidomide Plus Docetaxel in Prostate Cancer December 2006 September 2008
NCT01659658 Terminated Phase 3 Study of Dexamethasone Plus IXAZOMIB (MLN9708) or Physicians Choice of Treatment in Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis December 26, 2012 July 11, 2022
NCT03341494 Unknown status Phase 2 EGFR Mutation Positive NSCLC Patients With Gefitinib and Thalidomide April 1, 2017 November 1, 2020
NCT00155272 Unknown status Phase 1/Phase 2 Radiotherapy Plus Thalidomide in Locally Advanced Hepatocellular Carcinoma March 2005 August 2005
NCT03601871 Unknown status N/A The Efficacy and Safety of Thalidomide in Preventing CINV Induced by Cisplatin-containing Chemotherapy July 12, 2018 December 30, 2020
NCT01134484 Unknown status Phase 3 VELCADE-Thalidomide-Dexamethasone (VTD) vs Thalidomide-Dexamethasone (TD) Incorporated Into Double Autotransplantation for Untreated Multiple Myeloma (MM) May 2006 December 2015
NCT00276705 Unknown status Phase 2 Combination Chemotherapy and Thalidomide in Treating Younger Patients Undergoing Surgery For Newly Diagnosed Liver Cancer June 2005
NCT04612582 Unknown status Phase 4 Comparison of BTD and BCD Based Regimens in the Treatment of AL Amyloidosis January 1, 2020 June 30, 2023
NCT02085655 Unknown status Phase 3 PEG-ASP+Gemox Regimen and Thalidomide for NK/T Lymphoma April 25, 2013 December 31, 2022
NCT02145715 Unknown status Phase 1/Phase 2 Velcade, Thalidomide, Dexamethasone and Panobinostat Treatment and Panobinostat Maintenance in Multiple Myeloma January 2013 January 2016
NCT04680195 Unknown status Phase 2 Thalidomide in the Treatment of Chronic Radiation Proctitis With Intractable Bleeding December 14, 2020 December 30, 2022
NCT02248428 Unknown status Phase 3 Clarithromycin Plus CTd Regimen for Patients With Newly Diagnosed Multiple Myeloma April 2012 September 2020
NCT00026416 Unknown status Phase 2 Interferon Alfa and Thalidomide in Treating Patients With Soft Tissue Sarcoma or Bone Sarcoma October 2001
NCT00319865 Unknown status Phase 2 PAD Combination Therapy Followed by Thal/Dex for Relapsed or Refractory Multiple Myeloma November 2005 September 2008
NCT00349115 Unknown status Phase 2 TCD Followed by autoSCT for Newly Diagnosed MM Patients June 2006 June 2008
NCT00027664 Unknown status Phase 2 Interferon Alfa With or Without Thalidomide in Treating Patients With Metastatic Kidney Cancer February 2001
NCT00028886 Unknown status Phase 3 Combination Chemotherapy With or Without Thalidomide in Treating Patients With Multiple Myeloma March 2001
NCT02387086 Unknown status Phase 2/Phase 3 Gefitinib Combined With Thalidomide to Treat NSCLC May 2015 May 2017
NCT02401971 Unknown status Phase 4 Irinotecan Plus Thalidomide in Second Line Advanced Gastric Cancer August 2014 August 2018
NCT00033709 Unknown status Phase 2 Temozolomide and Thalidomide in Treating Patients With Metastatic, Locally Advanced, or Unresectable Leiomyosarcoma March 2002
NCT02467647 Unknown status Phase 1 The Effects of Huang-Lian-Jie-Du-Tang（HLJDT) on the Survival of Patients With Multiple Myeloma in Maintain Therapy January 2015 December 2019
NCT05266820 Unknown status Phase 2 Trifluridine/Tipiracil (TAS-102) With or Without Thalidomide for the Treatment of Metastatic Colorectal Cancer October 1, 2021 December 1, 2023
NCT00438841 Unknown status Phase 2 Bortezomib, Cyclophosphamide, Dexamethasone, and Thalidomide in Treating Patients With Newly Diagnosed, Previously Untreated Multiple Myeloma August 2006
NCT02559154 Unknown status Phase 4 Modified Bortezomib-based Combination Therapy for Multiple Myeloma July 2010 December 2018
NCT02649101 Unknown status Phase 2 Thalidomide Plus Chemotherapy Versus Chemotherapy Alone for Advanced Breast Cancer October 2015 October 2017
NCT02733380 Unknown status Phase 2 Chidamide Combined With VDDT Regimen in the Relapse and Refractory Diffuse Large B Cell Lymphoma May 2016 May 2021
NCT02778893 Unknown status Phase 4 Conmana Combined With Thalidomide to Treat NSCLC March 2016 March 2020
NCT02844309 Unknown status Phase 4 The Efficacy of TCD Following by TP Maintenance Therapy in Newly Diagnosed WM May 2016 May 2020
NCT02858804 Unknown status Phase 4 EDOCH Alternating With DHAP for New Diagnosed Younger MCL January 2016 June 2020
NCT02870036 Unknown status Phase 1 Study to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetics of Simmitecan Monotherapy and Combination in Patients With Advanced Solid Tumors October 2016 December 2020
NCT02956538 Unknown status Early Phase 1 Induced Adult Refractory Active Crohn's Disease Clinical Relieving by Using Thalidomide October 2016 October 2018
NCT02966522 Unknown status Phase 2 Thalidomide/Dexamethasone Treatment And PET Evaluation In Organ Involvemenet of Cardiac Amyloidosis October 2016 September 2019
NCT02995707 Unknown status Phase 2 The Effective and Safety of Thalidomide in NTDT September 2016 March 2018
NCT02998827 Unknown status N/A Thalidomide Results in Diminished Ovarian Reserve in Reproductive Age Female IBD Patients November 2016
NCT03016000 Unknown status Phase 3 Thalidomide Maintenance Treatment in DLBCL July 26, 2017 December 2023
NCT00728078 Unknown status Phase 2/Phase 3 Low-Dose Thalidomide as Adjuvant Therapy After Radiofrequency Ablation for Hepatocellular Carcinoma July 2008 July 2011
NCT03062800 Unknown status Phase 2 Study of Thalidomide in Treatment of Advanced Nsclc (Dream-003) December 2016 November 2021
NCT00856804 Unknown status Phase 2 Thalidomide Plus Peginterferon and Ribavirin in Patients With Interferon Resistance March 2009 June 2012
NCT00006200 Unknown status Phase 2 Thalidomide and Dacarbazine for Metastatic Melanoma
NCT00006198 Unknown status Phase 2 Chronic Thalidomide Administration in Patients Undergoing Chemoembolization for Unresectable Hepatocellular Cancer
NCT00921531 Unknown status Phase 3 Adjuvant Therapy With Thalidomide for Chemoembolization in Advanced Hepatocellular Carcinoma June 2009 April 2013
NCT00958854 Unknown status Phase 2 Fludarabine, Cyclophosphamide, and Thalidomide in Treating Patients With Angioimmunoblastic T-Cell Lymphoma January 2006
NCT03184844 Unknown status Phase 2 The Effective and Safety of Thalidomide in TI May 2, 2017 May 2, 2019
NCT03204032 Unknown status Phase 2 A Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Extrapancreatic Neuroendocrine Tumor October 2016 September 2018
NCT03208413 Unknown status Phase 2 The Therapeutic Effect of Thalidomide in RI July 19, 2017 July 30, 2020
NCT01094340 Unknown status Phase 2/Phase 3 Thalidomide for Patients With Mild to Moderate Alzheimer's Disease March 2010 January 2013
NCT00124813 Unknown status Phase 2 Thalidomide, Cyclophosphamide, Oral Idarubicin and Dexamethasone (T-CID) in Patients With Multiple Myeloma August 2002 November 2010
NCT01551641 Unknown status Phase 2 Phase II Trial of Thalidomide Combined With Concurrent Chemoradiotherapy in Esophageal Cancer January 2012 March 2016
NCT04273529 Unknown status Phase 2 The Efficacy and Safety of Thalidomide in the Adjuvant Treatment of Moderate New Coronavirus (COVID-19) Pneumonia February 20, 2020 June 30, 2020
NCT01638078 Unknown status Phase 4 Thalidomide fOr the Prevention of Restenosis After Coronary ArtERy Stent Implantation January 2014 December 2017
NCT01640639 Unknown status Phase 4 THalidomide on Left ventricUlar Morphology aND Function in congEstive heaRt Failure July 2012 December 2014
NCT04273581 Unknown status Phase 2 The Efficacy and Safety of Thalidomide Combined With Low-dose Hormones in the Treatment of Severe COVID-19 February 18, 2020 May 30, 2020
NCT01924624 Unknown status N/A Adjuvant Therapy With Thalidomide After Curative Resection of Hepatocellular Carcinoma July 2013 December 2019
NCT01976195 Withdrawn Phase 2 High-dose Dexamethasone Combining Thalidomide Versus Dexamethasone Mono-therapy for Management of Newly-diagnosed ITP October 2013
NCT00787436 Withdrawn Phase 3 Secondary Prophylaxis of Gastrointestinal Bleeding in Cirrhotic Patients Using THALIDOMIDE May 2006 January 2010
NCT00723658 Withdrawn Phase 2 S0629, Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants in Treating Patients With Waldenstrom Macroglobulinemia September 2008
NCT00025519 Withdrawn Phase 2 Peripheral Stem Cell Transplantation in Treating Patients With Metastatic or Recurrent Kidney Cancer June 2001 October 2006
NCT03608501 Withdrawn Phase 2 A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation September 30, 2019 May 31, 2023
NCT02754960 Withdrawn Phase 2 Efficacy Study of Thalidomide in Gastrointestinal Vascular Malformation Related Bleeding March 2010 September 2014
NCT00112879 Withdrawn Phase 2 Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Treating Patients With Multiple Myeloma
NCT01055301 Withdrawn Phase 2 S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma July 2011 July 2011
NCT00390247 Withdrawn Phase 4 Thalidomide for the Treatment of Malnutrition Inflammation Syndrome in Peritoneal Dialysis Patients January 2007 December 2008
NCT02301949 Withdrawn Phase 2 Retreatment and Its Efficiency of Thalidomide for Vascular Malformation Patients With Failure of First Course Treatment December 2015 December 2018